Your browser is no longer supported. Please, upgrade your browser.
Settings
CORT [NASD]
Corcept Therapeutics Incorporated
Index- P/E25.61 EPS (ttm)0.84 Insider Own0.10% Shs Outstand115.79M Perf Week-6.24%
Market Cap2.49B Forward P/E23.69 EPS next Y0.91 Insider Trans-14.74% Shs Float103.94M Perf Month22.17%
Income106.50M PEG- EPS next Q0.24 Inst Own71.30% Short Float8.88% Perf Quarter-0.19%
Sales352.90M P/S7.05 EPS this Y11.10% Inst Trans0.14% Short Ratio15.26 Perf Half Y-0.51%
Book/sh4.67 P/B4.60 EPS next Y5.47% ROA18.70% Target Price27.67 Perf Year-5.87%
Cash/sh3.12 P/C6.88 EPS next 5Y- ROE20.30% 52W Range17.57 - 31.18 Perf YTD-17.85%
Dividend- P/FCF16.28 EPS past 5Y74.60% ROI19.60% 52W High-31.08% Beta0.66
Dividend %- Quick Ratio8.90 Sales past 5Y47.70% Gross Margin98.50% 52W Low22.31% ATR0.82
Employees236 Current Ratio9.00 Sales Q/Q11.40% Oper. Margin33.50% RSI (14)49.88 Volatility3.58% 3.72%
OptionableYes Debt/Eq0.00 EPS Q/Q40.10% Profit Margin30.20% Rel Volume0.76 Prev Close22.46
ShortableYes LT Debt/Eq0.00 EarningsNov 03 AMC Payout0.00% Avg Volume604.97K Price21.49
Recom2.50 SMA200.37% SMA504.93% SMA200-2.49% Volume460,944 Change-4.32%
Aug-05-20Downgrade Jefferies Buy → Hold $16
Sep-24-19Initiated Jefferies Buy $20
Sep-06-19Initiated H.C. Wainwright Buy $18
Feb-04-19Downgrade B. Riley FBR Buy → Neutral $22 → $12
Aug-10-18Reiterated Stifel Hold $20 → $11
May-31-18Downgrade Stifel Buy → Hold $20
Mar-09-18Initiated B. Riley FBR, Inc. Buy $30
Aug-31-17Initiated Stifel Buy $20
Feb-02-17Initiated Ladenburg Thalmann Buy $14
Apr-21-15Initiated FBR Capital Outperform $12
Jan-13-14Downgrade Stifel Buy → Hold
Aug-09-13Downgrade Ladenburg Thalmann Buy → Neutral $3.30
Aug-09-13Downgrade Janney Buy → Neutral
Feb-21-12Reiterated JMP Securities Mkt Outperform $9 → $11
Jan-06-10Upgrade Ladenburg Thalmann Neutral → Buy $4
Jul-17-08Initiated Rodman & Renshaw Mkt Outperform $8
Jun-21-07Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
Nov-24-21 09:04AM  
06:00AM  
Nov-10-21 08:30AM  
Nov-08-21 08:30AM  
Nov-04-21 09:48AM  
Nov-03-21 09:01PM  
06:15PM  
04:05PM  
Oct-27-21 04:05PM  
Oct-26-21 03:02PM  
Oct-12-21 08:25AM  
06:45AM  
Oct-06-21 11:30AM  
Oct-04-21 10:23AM  
Sep-30-21 07:00AM  
Sep-28-21 08:00AM  
Sep-17-21 10:53AM  
08:30AM  
Sep-16-21 11:26AM  
Sep-09-21 04:05PM  
Sep-08-21 07:00AM  
Aug-12-21 05:00PM  
Jul-30-21 01:33PM  
04:32AM  
Jul-29-21 06:35PM  
04:05PM  
Jul-27-21 11:40AM  
Jul-23-21 02:29AM  
Jul-22-21 04:05PM  
Jul-15-21 10:43AM  
Jul-12-21 08:30AM  
Jun-22-21 10:36AM  
08:30AM  
Jun-17-21 02:53AM  
Jun-16-21 05:00AM  
Jun-15-21 08:30AM  
Jun-10-21 07:30AM  
May-14-21 09:15AM  
May-07-21 12:17PM  
10:09AM  
06:56AM  
06:31AM  
May-06-21 05:20PM  
04:10PM  
04:05PM  
04:01PM  
02:45PM  
May-05-21 06:32AM  
Apr-29-21 04:05PM  
Apr-26-21 12:31PM  
Apr-05-21 02:42AM  
Mar-25-21 11:30AM  
Mar-24-21 06:12AM  
Mar-16-21 09:34AM  
Mar-15-21 07:30AM  
Mar-01-21 04:05PM  
Feb-23-21 04:05PM  
Feb-19-21 01:26AM  
Feb-14-21 01:32PM  
Feb-10-21 11:40AM  
Feb-09-21 09:54AM  
Feb-08-21 11:00PM  
04:05PM  
03:15PM  
Feb-05-21 08:36AM  
Feb-01-21 04:05PM  
Jan-20-21 12:05AM  
Dec-31-20 09:40AM  
Dec-21-20 12:20AM  
Dec-19-20 06:23PM  
Dec-03-20 11:30AM  
Nov-23-20 05:00PM  
Nov-18-20 05:40PM  
Nov-13-20 05:36AM  
Nov-05-20 10:53AM  
Nov-04-20 12:08PM  
Nov-03-20 05:15PM  
04:29PM  
04:05PM  
03:15PM  
Oct-27-20 04:05PM  
Oct-16-20 08:00AM  
Oct-07-20 10:26AM  
Oct-05-20 12:46PM  
Sep-29-20 09:00AM  
Sep-24-20 07:10AM  
Sep-18-20 07:26AM  
Sep-17-20 10:56AM  
Sep-10-20 08:30AM  
Sep-08-20 04:34AM  
Sep-04-20 11:41AM  
07:04AM  
Sep-03-20 11:31AM  
09:50AM  
08:44AM  
06:31AM  
Sep-01-20 09:34AM  
Aug-05-20 05:56PM  
02:11PM  
02:01AM  
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Maduck SeanChief Commercial OfficerOct 05Option Exercise3.296372,09640,661Oct 05 06:17 PM
Maduck SeanChief Commercial OfficerOct 05Sale20.0063712,74040,024Oct 05 06:17 PM
Maduck SeanChief Commercial OfficerOct 01Option Exercise3.2924,36380,15464,387Oct 05 06:17 PM
Maduck SeanChief Commercial OfficerOct 01Sale20.0024,363487,37540,024Oct 05 06:17 PM
Robb Gary CharlesChief Business OfficerSep 15Sale20.4947,853980,74287,848Sep 15 06:13 PM
Robb Gary CharlesChief Business OfficerSep 14Sale20.7680616,736135,701Sep 15 06:13 PM
Robb Gary CharlesChief Business OfficerSep 13Sale20.896,341132,445136,507Sep 15 06:13 PM
Swisher Daniel N JRDirectorSep 02Option Exercise6.557,50049,1257,500Sep 03 05:30 PM
Swisher Daniel N JRDirectorSep 02Sale21.707,500162,7410Sep 03 05:30 PM
Maduck SeanChief Commercial OfficerSep 01Option Exercise3.2925,00082,25065,024Sep 03 05:10 PM
Maduck SeanChief Commercial OfficerSep 01Sale21.4025,000534,93040,024Sep 03 05:10 PM
Robb Gary CharlesChief Business OfficerAug 30Option Exercise2.70148,148400,000223,786Sep 01 05:36 PM
Maduck SeanChief Commercial OfficerAug 03Option Exercise3.2925,00082,25065,024Aug 05 05:30 PM
Maduck SeanChief Commercial OfficerAug 03Sale21.1825,000529,42040,024Aug 05 05:30 PM
Hunt HazelChief Scientific OfficerJul 14Option Exercise2.8950,000144,50068,975Jul 16 05:14 PM
Maduck SeanChief Commercial OfficerJul 13Option Exercise2.2410,00022,40040,024Jul 14 05:08 PM
Maduck SeanChief Commercial OfficerJul 07Option Exercise3.2925,00082,25055,024Jul 09 05:29 PM
Maduck SeanChief Commercial OfficerJul 07Sale22.1925,000554,69230,024Jul 09 05:29 PM
BAKER G LEONARD JRDirectorJun 11Buy21.53100,0002,153,0003,308,303Jun 15 07:01 PM
BAKER G LEONARD JRDirectorJun 11Buy21.5350,0001,076,5001,046,838Jun 15 07:01 PM
Swisher Daniel N JRDirectorJun 02Option Exercise6.557,50049,1257,500Jun 04 06:56 PM
Swisher Daniel N JRDirectorJun 02Sale21.487,500161,0850Jun 04 06:56 PM
BAKER G LEONARD JRDirectorMay 18Option Exercise3.70150,000555,0001,146,838May 20 06:35 PM
MAHONEY DAVID LDirectorMay 11Option Exercise4.4230,000132,600118,984May 13 05:40 PM
Robb Gary CharlesChief Financial OfficerApr 23Sale24.0210,000240,21975,638Apr 27 06:30 PM
WILSON JAMES NDirectorApr 14Option Exercise4.42200,000884,000200,000Apr 16 09:08 PM
Swisher Daniel N JRDirectorApr 05Option Exercise6.557,50049,1257,500Apr 07 05:20 PM
Swisher Daniel N JRDirectorApr 05Sale24.147,500181,0360Apr 07 05:20 PM
Lyon Joseph DouglasChief Accounting OfficerApr 01Option Exercise11.3525,000283,75025,000Apr 05 05:12 PM
Lyon Joseph DouglasChief Accounting OfficerApr 01Sale23.8825,000597,0300Apr 05 05:12 PM
Lyon Joseph DouglasChief Accounting OfficerMar 01Option Exercise8.2725,000206,75025,000Mar 03 05:38 PM
Lyon Joseph DouglasChief Accounting OfficerMar 01Sale25.2125,000630,3200Mar 03 05:38 PM
Maduck SeanSee RemarksFeb 16Option Exercise3.298,98929,57439,013Feb 16 08:50 PM
Maduck SeanSee RemarksFeb 16Sale28.258,989253,90330,024Feb 16 08:50 PM
Robb Gary CharlesChief Financial OfficerFeb 12Sale28.22112,1003,163,89985,638Feb 16 08:15 PM
Maduck SeanSee RemarksFeb 11Option Exercise3.293,40011,18633,424Feb 16 08:50 PM
Maduck SeanSee RemarksFeb 11Sale29.783,400101,24930,024Feb 16 08:50 PM
Robb Gary CharlesChief Financial OfficerFeb 11Sale29.783,400101,249197,738Feb 16 08:15 PM
Lyon Joseph DouglasChief Accounting OfficerFeb 03Option Exercise8.2725,000206,75025,000Feb 04 07:13 PM
Lyon Joseph DouglasChief Accounting OfficerFeb 03Sale29.1825,000729,5700Feb 04 07:13 PM
Robb Gary CharlesChief Financial OfficerJan 22Option Exercise2.70451,8521,220,000459,877Jan 26 09:35 PM
BELANOFF JOSEPH KChief Executive OfficerJan 22Option Exercise4.42800,0003,536,0003,299,214Jan 26 09:33 PM
Swisher Daniel N JRDirectorJan 19Option Exercise6.555,00032,7505,000Jan 21 05:05 PM
Swisher Daniel N JRDirectorJan 19Sale28.745,000143,6860Jan 21 05:05 PM
Lyon Joseph DouglasChief Accounting OfficerJan 04Option Exercise8.2725,000206,75025,000Jan 04 07:43 PM
Lyon Joseph DouglasChief Accounting OfficerJan 04Sale26.1325,000653,3450Jan 04 07:43 PM
Lyon Joseph DouglasChief Accounting OfficerDec 30Option Exercise7.5425,000188,45725,000Jan 04 07:43 PM
Lyon Joseph DouglasChief Accounting OfficerDec 30Sale26.0725,000651,7520Jan 04 07:43 PM
BAKER G LEONARD JRDirectorDec 01Buy22.64681,5403,208,303Dec 02 07:41 PM
BAKER G LEONARD JRDirectorNov 30Buy22.801,10925,2853,208,235Dec 02 07:41 PM